Anis Thaqifah Mat Habib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anis Thaqifah Mat Habib has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abul Kalam Najmi
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
1 shared publication - Ambrish Singh
Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia
1 shared publication - Azlizan Talib
Ghazali Shafie Graduate School of Government (GSGSG), Universiti Utara Malaysia, Malaysia
1 shared publication - Mohd Akhtar
Department of Pharmacology, School of Pharmaceutical Education and Research Jamia Hamdard New Delhi India
1 shared publication - Muhamad Azwan Abd Rahman
The Institute of Malaysian and International Studies, Universiti Kebangsaan Malaysia, Malaysia
1 shared publication Nik Hasif
The Institute of Malaysian and International Studies, Universiti Kebangsaan Malaysia, Malaysia
1 shared publication
Latest Publications
- Open Access
- 30 April 2025
- Published by UUM Press, Universiti Utara Malaysia in Journal of International Studies
- Vol. 21 (1) , 96-111
MALAYSIA'S STATE AUTONOMY STATUS IN CHINA'S BELT AND ROAD INITIATIVE PARTNERSHIP
The Belt and Road Initiative (BRI), introduced by Xi Jinping in September 2013, has become a significant component of China's global economic strategy, impacting its numerous partner countries, including Malaysia. This study examines Malaysia's state autonomy in managing its relationship with China within the BRI framework under Anwar Ibrahim's leadership. While the initiative presents economic benefits, Malaysia faces challenges in balancing its autonomy with its strategic and comprehensive engagement in BRI projects. This study employs a qualitative approach, drawing insights from both primary and secondary sources. Primary data were collected through interviews with government officials, industry experts, and relevant stakeholders, while secondary sources included existing literature, reports, and official documents. The study assesses Malaysia's strategic approach to maintaining autonomy within the BRI partnership, identifies key factors influencing Malaysia's decision-making regarding BRI projects, and examines the broader implications of Malaysia's state autonomy on its economy and national interests. Supported by Anthony Giddens’ structuration framework, the findings shed light on Malaysia's governance strategies and interactions with China under the BRI. By analysing the dynamics of state autonomy in this partnership, the study provides valuable insights of the BRI’s implications for Malaysia's sovereignty, economic development, and foreign policy.
- 30 April 2025
- Published by UUM Press, Universiti Utara Malaysia in Journal of International Studies
- Vol. 21 (1) , 96-111
Open AccessMALAYSIA'S STATE AUTONOMY STATUS IN CHINA'S BELT AND ROAD INITIATIVE PARTNERSHIP
The Belt and Road Initiative (BRI), introduced by Xi Jinping in September 2013, has become a significant component of China's global economic strategy, impacting its numerous partner countries, including Malaysia. This study examines Malaysia's state autonomy in managing its relationship with China within the BRI framework under Anwar Ibrahim's leadership. While the initiative presents economic benefits, Malaysia faces challenges in balancing its autonomy with its strategic and comprehensive engagement in BRI projects. This study employs a qualitative approach, drawing insights from both primary and secondary sources. Primary data were collected through interviews with government officials, industry experts, and relevant stakeholders, while secondary sources included existing literature, reports, and official documents. The study assesses Malaysia's strategic approach to maintaining autonomy within the BRI partnership, identifies key factors influencing Malaysia's decision-making regarding BRI projects, and examines the broader implications of Malaysia's state autonomy on its economy and national interests. Supported by Anthony Giddens’ structuration framework, the findings shed light on Malaysia's governance strategies and interactions with China under the BRI. By analysing the dynamics of state autonomy in this partnership, the study provides valuable insights of the BRI’s implications for Malaysia's sovereignty, economic development, and foreign policy.
- Open Access
- 1 January 2020
- Published by Medknow in Saudi Journal of Kidney Diseases and Transplantation
- Vol. 31 (5) , 883-897
Nicotinamide Therapy in Dialysis Patients: A Systematic Review of Randomized Controlled Trials
Randomized controlled trials (RCTs) have presented variable findings concerning the reduction of phosphorous level by nicotinamide. This systematic review is aimed to explore the safety and efficacy of nicotinamide in hemodialysis patients and was conducted by adhering to the PRISMA guidelines. Studies for inclusion were identified by running the suitable keywords in PubMed, Embase, and Cochrane Central till June 13, 2018. Cochrane risk of bias tool was used to judge the quality of the included RCTs. The primary outcome was change in serum phosphorus, calcium, and calcium–phosphorus product levels. Change in other biochemical parameters including serum calcium, parathormone, platelets, lipid profile parameters, and the safety profile was considered under secondary outcomes. Review Manager (RevMan v5.3) was used for the risk of bias estimate. A total of 12 articles were qualified for inclusion in this study. All the included RCTs showed a statistically significant reduction in mean serum phosphorous and calcium–phosphorus product levels in the treatment arm as compared to the placebo group. Among several biochemical parameters analyzed, only high-density lipoprotein (HDL) was found to be significantly increased from baseline to the endpoint of the study in the nicotinamide group, while the placebo group showed no significant difference. Flushing and diarrhea, followed by thrombocytopenia, were the most commonly reported adverse events in the treatment group. Nicotinamide was found to be effective in reducing the phosphorous level and calcium–phosphorus product level and increasing the HDL cholesterol level in dialysis patients. The safety profile was found to be satisfactory.
- 1 January 2020
- Published by Medknow in Saudi Journal of Kidney Diseases and Transplantation
- Vol. 31 (5) , 883-897
Open AccessNicotinamide Therapy in Dialysis Patients: A Systematic Review of Randomized Controlled Trials
Randomized controlled trials (RCTs) have presented variable findings concerning the reduction of phosphorous level by nicotinamide. This systematic review is aimed to explore the safety and efficacy of nicotinamide in hemodialysis patients and was conducted by adhering to the PRISMA guidelines. Studies for inclusion were identified by running the suitable keywords in PubMed, Embase, and Cochrane Central till June 13, 2018. Cochrane risk of bias tool was used to judge the quality of the included RCTs. The primary outcome was change in serum phosphorus, calcium, and calcium–phosphorus product levels. Change in other biochemical parameters including serum calcium, parathormone, platelets, lipid profile parameters, and the safety profile was considered under secondary outcomes. Review Manager (RevMan v5.3) was used for the risk of bias estimate. A total of 12 articles were qualified for inclusion in this study. All the included RCTs showed a statistically significant reduction in mean serum phosphorous and calcium–phosphorus product levels in the treatment arm as compared to the placebo group. Among several biochemical parameters analyzed, only high-density lipoprotein (HDL) was found to be significantly increased from baseline to the endpoint of the study in the nicotinamide group, while the placebo group showed no significant difference. Flushing and diarrhea, followed by thrombocytopenia, were the most commonly reported adverse events in the treatment group. Nicotinamide was found to be effective in reducing the phosphorous level and calcium–phosphorus product level and increasing the HDL cholesterol level in dialysis patients. The safety profile was found to be satisfactory.